Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
IPO Year: 2019
Exchange: NYSE
Website: alcon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2025 | Neutral → Buy | BofA Securities | |
| 1/24/2025 | $108.00 → $106.00 | Buy | Needham |
| 1/10/2025 | Neutral → Buy | Redburn Atlantic | |
| 12/17/2024 | $103.00 → $108.00 | Buy | Needham |
| 11/12/2024 | Buy | Needham | |
| 10/10/2024 | Sell → Neutral | Redburn Atlantic | |
| 9/10/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
| 7/15/2024 | $65.00 → $85.00 | Underweight → Equal-Weight | Morgan Stanley |
| 5/15/2024 | $103.00 | Perform → Outperform | Oppenheimer |
| 4/10/2024 | $100.00 | Buy | Goldman |
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
20-F - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
SD - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
BofA Securities upgraded Alcon from Neutral to Buy
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $106.00 from $108.00 previously
Redburn Atlantic upgraded Alcon from Neutral to Buy
Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $108.00 from $103.00 previously
Needham reiterated coverage of Alcon with a rating of Buy
Redburn Atlantic upgraded Alcon from Sell to Neutral
RBC Capital Mkts upgraded Alcon from Sector Perform to Outperform
Morgan Stanley upgraded Alcon from Underweight to Equal-Weight and set a new price target of $85.00 from $65.00 previously
Oppenheimer upgraded Alcon from Perform to Outperform and set a new price target of $103.00
Goldman initiated coverage of Alcon with a rating of Buy and set a new price target of $100.00
Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate equity incentive plans Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte
Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as
First-quarter 2024 sales of $2.4 billion, up 5%, or 7% constant currency1 (cc) First-quarter 2024 diluted EPS of $0.50, up 43%, or 62% cc; core diluted EPS2 of $0.78 up 11%, or 21% cc First-quarter 2024 cash from operations of $341 million; free cash flow3 of $229 million, up $248 million year-over year Dividend of CHF 0.24 per share approved by shareholders at the Annual General Meeting on May 8, 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a consta
Shareholders approve dividend of CHF 0.24 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve the 2023 Non-Financial Matters Report in an advisory vote Shareholders approve the Board and Executive Committee compensation in separate binding votes Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM). A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of
Alcon welcomes its shareholders to its second in-person AGM In addition to the regular agenda items, shareholders to vote on the Report on Non-Financial Matters Proposed dividend of CHF 0.24 cash per share Alcon (NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to t
Q4 2023 sales of $2.3 billion, up 8%, or 10% constant currency(1) (cc) Q4 2023 diluted EPS of $0.86, compared to a loss in the prior year(3); core diluted EPS(2) of $0.70 up 67%, or 78% cc FY 2023 sales of $9.4 billion, up 8%, or 10% cc FY 2023 diluted EPS of $1.96, up 188%; core diluted EPS of $2.74, up 22%, or 33% cc FY 2024 outlook: 6% to 8% cc sales growth, 13% to 16% cc core diluted EPS growth Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2023. For the fourth quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and
Third quarter 2023 sales of $2.3 billion, up 8%, or 9% constant currency(1) (cc) Third quarter 2023 diluted EPS of $0.41, up 78%, or up 97% cc; core diluted EPS(2) of $0.66 up 32%, or 41% cc Generated $937 million of cash from operating activities and $592 million of free cash flow(3) in the first nine months of 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2023. For the third quarter of 2023, sales were $2.3 billion, an increase of 8% on a reported basis and 9% on a constant currency basis(1), as compared to the same quarter of the previous year.
Second quarter 2023 sales of $2.4 billion, up 9%, or 12% constant currency(1) (cc) Second quarter 2023 diluted EPS of $0.34, up 13%, or up 34% cc; core diluted EPS(2) of $0.69 up 10%, or 19% cc Based on strong operational performance and improved outlook, Company raises full year 2023 sales and core diluted EPS guidance Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three and six months ended June 30, 2023. For the second quarter of 2023, sales were $2.4 billion, an increase of 9% on a reported basis and 12% on a constant currency basis(1), as compared to the same quarter of the previous year.
First quarter 2023 sales of $2.3 billion, up 7%, or 11% constant currency(1) (cc) First quarter 2023 diluted EPS of $0.35, up 3%, or up 26% cc; core diluted EPS(2) of $0.70 up 3%, or 14% cc Dividend of CHF 0.21 per share approved by shareholders at the Annual General Meeting on May 5, 2023 Raised full year 2023 cc sales and core diluted EPS growth outlook Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2023. For the first quarter of 2023, sales were $2.3 billion, an increase of 7% on a reported basis and 11% on a constant currency basis(1), as compared to the same
Clareon Vivity IOL provides an extended range of vision from distance to functional near with a monofocal visual disturbance profile1-3µ‖ Vivity, the world's leading EDOF, is now available on Alcon's Clareon material, providing presbyopia correction with exceptional† clarity and predictable refractive outcomes1,4-7 CE Marked countries will begin commercial rollout of Clareon Vivity and Clareon Vivity Toric from early Q2 2025; also available in AutonoMe automated pre-loaded delivery system in Q3 20258 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity®, the most widely implanted9 extended depth of focus (EDOF)
Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolioNext generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ:LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment Sy
Alcon (SIX/NYSE:ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2025/Alcons-2025-Capital-Markets-Day-2025-6w85_Spqte/default.aspx. Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical an
TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 is now available in expanded parameters Features the same 95% fit success rate and innovative PRECISION BALANCE 8|4 technology4* New expanded parameters help more astigmatic patients address unmet needs for comfort5 and convenience in a monthly lens Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –
Full-year 2024 sales of $9.8 billion, up 5%, or up 6% constant currency1 (cc) Full-year 2024 diluted EPS of $2.05, up 5% on a reported basis, or up 11% cc; core diluted EPS2 of $3.05 up 11% on a reported basis, or up 16% cc Generated record $2.1 billion of cash from operations in full-year 2024; record free cash flow3 of $1.6 billion, up 120% Announced share repurchase authorization to offset dilution from associate equity incentive plans Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5
SYSTANE PRO Preservative-Free (PF) is the longest lasting dry eye drop in the SYSTANE portfolio1 SYSTANE PRO PF is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes1 SYSTANE PRO PF will be showcased at SECO 2025 as the latest addition to the SYSTANE line of products, the #1 global consumer brand of artificial tears2 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE® PRO Preservative-Free (PF) as the latest over-the-counter eye drop in the company's dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in t
New first-line laser treatment for the nearly 5 million Americans diagnosed with glaucoma1,2 Automated device enables a streamlined workflow without a gonio lens or manual aiming2 Voyager Direct Selective Laser Trabeculoplasty (DSLT) will be launched at the American Glaucoma Society annual meeting in Washington, D.C. Alcon (SIX/NYSE:ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager™ DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment's availabilit
Alcon (SIX/NYSE:ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than
Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23%, or 25% cc Generated $1.6 billion of cash from operations in the first nine months of 2024; record free cash flow3 of $1.3 billion, up $704 million, or 119% Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarte
PRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision, even on day 71 Features world's first ACTIV-FLO System specially designed for one-week optimal performance2 PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for comfort and affordability when a daily disposable lens is not an option1,3* Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7®, the only one-week replacement contact lens with the revolutionary 7-day ACTIV-FLO® System2 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 Wh